Skip to main content
Top
Published in: Sports Medicine 9/2020

01-09-2020 | Malignant Hyperthermia | Review Article

Overlapping Mechanisms of Exertional Heat Stroke and Malignant Hyperthermia: Evidence vs. Conjecture

Authors: Orlando Laitano, Kevin O. Murray, Lisa R. Leon

Published in: Sports Medicine | Issue 9/2020

Login to get access

Abstract

Exertional heat stroke (EHS) and malignant hyperthermia (MH) are life-threatening conditions, triggered by different environmental stimuli that share several clinical symptoms and pathophysiological features. EHS manifests during physical activity normally, but not always, in hot and humid environments. MH manifests during exposure to haloalkane anesthetics or succinylcholine, which leads to a rapid, unregulated release of calcium (Ca2+) within the skeletal muscles inducing a positive-feedback loop within the excitation–contraction coupling mechanism that culminates in heat stroke-like symptoms, if not rapidly recognized and treated. Rare cases of awake MH, independent of anesthesia exposure, occur during exercise and heat stress. It has been suggested that EHS and MH are mediated by similar mechanisms, including mutations in Ca2+ regulatory channels within the skeletal muscle. Rapid cooling, which is the most effective treatment for EHS, is ineffective as an MH treatment; rather, a ryanodine receptor antagonist drug, dantrolene sodium (DS), is administered to the victim to prevent further muscle contractions and hyperthermia. Whether DS can be an effective treatment for EHS victims remains uncertain. In the last decade, multiple reports have suggested a number of mechanistic links between EHS and MH. Here, we discuss aspects related to the pathophysiology, incidence, diagnosis and treatment. Furthermore, we present evidence regarding potential overlapping mechanisms between EHS and MH and explore current knowledge to establish what is supported by evidence or a lack thereof (i.e. conjecture).
Literature
3.
go back to reference Sawka MN, Leon LR, Montain SJ, Sonna LA. Integrated physiological mechanisms of exercise performance, adaptation, and maladaptation to heat stress. Compr Physiol. 2011;1:1883–928.PubMedCrossRef Sawka MN, Leon LR, Montain SJ, Sonna LA. Integrated physiological mechanisms of exercise performance, adaptation, and maladaptation to heat stress. Compr Physiol. 2011;1:1883–928.PubMedCrossRef
4.
go back to reference Roberts WO. Exertional heat stroke during a cool weather marathon: a case study. Med Sci Sports Exerc. 2006;38:1197–203.PubMedCrossRef Roberts WO. Exertional heat stroke during a cool weather marathon: a case study. Med Sci Sports Exerc. 2006;38:1197–203.PubMedCrossRef
5.
6.
go back to reference Appiah-Ankam J, Hunter JM. Pharmacology of neuromuscular blocking drugs. Contin Educ Anaesth Crit Care Pain. 2004;4:2–7.CrossRef Appiah-Ankam J, Hunter JM. Pharmacology of neuromuscular blocking drugs. Contin Educ Anaesth Crit Care Pain. 2004;4:2–7.CrossRef
7.
go back to reference Jardon OM. Physiologic stress, heat stroke, malignant hyperthermia—a perspective. Mil Med. 1982;147:8–14.PubMedCrossRef Jardon OM. Physiologic stress, heat stroke, malignant hyperthermia—a perspective. Mil Med. 1982;147:8–14.PubMedCrossRef
8.
go back to reference Lavezzi WA, Capacchione JF, Muldoon SM, Sambuughin N, Bina S, Steele D, et al. Death in the emergency department: an unrecognized awake malignant hyperthermia-like reaction in a six-year-old. Anesth Analg. 2013;116:420.PubMedCrossRef Lavezzi WA, Capacchione JF, Muldoon SM, Sambuughin N, Bina S, Steele D, et al. Death in the emergency department: an unrecognized awake malignant hyperthermia-like reaction in a six-year-old. Anesth Analg. 2013;116:420.PubMedCrossRef
9.
go back to reference Figarella-Branger D, Kozak-Ribbens G, Rodet L, Aubert M, Borsarelli J, Cozzone PJ, et al. Pathological findings in 165 patients explored for malignant hyperthermia susceptibility. Neuromuscul Disord. 1993;3:553–6.PubMedCrossRef Figarella-Branger D, Kozak-Ribbens G, Rodet L, Aubert M, Borsarelli J, Cozzone PJ, et al. Pathological findings in 165 patients explored for malignant hyperthermia susceptibility. Neuromuscul Disord. 1993;3:553–6.PubMedCrossRef
10.
go back to reference Ogletree JW, Antognini JF, Gronert GA. Postexercise muscle cramping associated with positive malignant hyperthermia contracture testing. Am J Sports Med. 1996;24:49–51.PubMedCrossRef Ogletree JW, Antognini JF, Gronert GA. Postexercise muscle cramping associated with positive malignant hyperthermia contracture testing. Am J Sports Med. 1996;24:49–51.PubMedCrossRef
11.
go back to reference Gronert GA, Thompson RL, Onofrio BM. Human malignant hyperthermia: awake episodes and correction by Dantrolene. Anesth Analg. 1980;59:377.PubMedCrossRef Gronert GA, Thompson RL, Onofrio BM. Human malignant hyperthermia: awake episodes and correction by Dantrolene. Anesth Analg. 1980;59:377.PubMedCrossRef
12.
go back to reference Fink E, Brandom BW, Torp KD. Heatstroke in the super-sized athlete. Pediatr Emerg Care. 2006;22:510.PubMedCrossRef Fink E, Brandom BW, Torp KD. Heatstroke in the super-sized athlete. Pediatr Emerg Care. 2006;22:510.PubMedCrossRef
13.
go back to reference Poussel M, Guerci P, Kaminsky P, Heymonet M, Roux-Buisson N, Faure J, et al. Exertional heat stroke and susceptibility to malignant hyperthermia in an athlete: evidence for a link? J Athl Train. 2015;50:1212–4.PubMedPubMedCentralCrossRef Poussel M, Guerci P, Kaminsky P, Heymonet M, Roux-Buisson N, Faure J, et al. Exertional heat stroke and susceptibility to malignant hyperthermia in an athlete: evidence for a link? J Athl Train. 2015;50:1212–4.PubMedPubMedCentralCrossRef
14.
go back to reference Hopkins PM, Ellis FR, Halsall PJ. Evidence for related myopathies in exertional heat stroke and malignant hyperthermia. Lancet. 1991;338:1491–2.PubMedCrossRef Hopkins PM, Ellis FR, Halsall PJ. Evidence for related myopathies in exertional heat stroke and malignant hyperthermia. Lancet. 1991;338:1491–2.PubMedCrossRef
15.
go back to reference Capacchione JF, Muldoon SM. The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesth Analg. 2009;109:1065.PubMedCrossRef Capacchione JF, Muldoon SM. The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesth Analg. 2009;109:1065.PubMedCrossRef
16.
go back to reference Muldoon S, Deuster P, Voelkel M, Capacchione J, Bunger R. Exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia: is there a link? Curr Sports Med Rep. 2008;7:74.PubMedCrossRef Muldoon S, Deuster P, Voelkel M, Capacchione J, Bunger R. Exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia: is there a link? Curr Sports Med Rep. 2008;7:74.PubMedCrossRef
17.
go back to reference Muldoon S, Deuster P, Brandom B, Bunger R. Is there a link between malignant hyperthermia and exertional heat illness? Exerc Sport Sci Rev. 2004;32:174.PubMedCrossRef Muldoon S, Deuster P, Brandom B, Bunger R. Is there a link between malignant hyperthermia and exertional heat illness? Exerc Sport Sci Rev. 2004;32:174.PubMedCrossRef
18.
go back to reference Laitano O, Leon LR, Roberts WO, Sawka MN. Controversies in exertional heat stroke diagnosis, prevention, and treatment. J Appl Physiol. 2019;127:1338–48.PubMedCrossRef Laitano O, Leon LR, Roberts WO, Sawka MN. Controversies in exertional heat stroke diagnosis, prevention, and treatment. J Appl Physiol. 2019;127:1338–48.PubMedCrossRef
19.
go back to reference Sagui E, Montigon C, Abriat A, Jouvion A, Duron-Martinaud S, Canini F, et al. Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia? PLoS ONE. 2015;10:e0135496.PubMedPubMedCentralCrossRef Sagui E, Montigon C, Abriat A, Jouvion A, Duron-Martinaud S, Canini F, et al. Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia? PLoS ONE. 2015;10:e0135496.PubMedPubMedCentralCrossRef
20.
go back to reference Nybo L, Rasmussen P, Sawka MN. Performance in the heat-physiological factors of importance for hyperthermia-induced fatigue. Compr Physiol. 2014;4:657–89.PubMedCrossRef Nybo L, Rasmussen P, Sawka MN. Performance in the heat-physiological factors of importance for hyperthermia-induced fatigue. Compr Physiol. 2014;4:657–89.PubMedCrossRef
21.
go back to reference González-Alonso J, Crandall CG, Johnson JM. The cardiovascular challenge of exercising in the heat. J Physiol (Lond). 2008;586:45–53.CrossRef González-Alonso J, Crandall CG, Johnson JM. The cardiovascular challenge of exercising in the heat. J Physiol (Lond). 2008;586:45–53.CrossRef
22.
go back to reference Casa DJ, DeMartini JK, Bergeron MF, Csillan D, Eichner ER, Lopez RM, et al. National athletic trainers’ association position statement: exertional heat illnesses. J Athl Train. 2015;50:986–1000.PubMedPubMedCentralCrossRef Casa DJ, DeMartini JK, Bergeron MF, Csillan D, Eichner ER, Lopez RM, et al. National athletic trainers’ association position statement: exertional heat illnesses. J Athl Train. 2015;50:986–1000.PubMedPubMedCentralCrossRef
23.
go back to reference Binkley HM, Beckett J, Casa DJ, Kleiner DM, Plummer PE. National athletic trainers’ association position statement: exertional heat illnesses. J Athl Train. 2002;37:329–43.PubMedPubMedCentral Binkley HM, Beckett J, Casa DJ, Kleiner DM, Plummer PE. National athletic trainers’ association position statement: exertional heat illnesses. J Athl Train. 2002;37:329–43.PubMedPubMedCentral
25.
go back to reference Larach MG, Rosenberg H, Larach DR, Broennle AM. Prediction of malignant hyperthermia susceptibility by clinical signs. Anesthesiology. 1987;66:547–50.PubMedCrossRef Larach MG, Rosenberg H, Larach DR, Broennle AM. Prediction of malignant hyperthermia susceptibility by clinical signs. Anesthesiology. 1987;66:547–50.PubMedCrossRef
26.
go back to reference Glahn KPE, Ellis FR, Halsall PJ, Müller CR, Snoeck MMJ, Urwyler A, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth. 2010;105:417–20.PubMedCrossRef Glahn KPE, Ellis FR, Halsall PJ, Müller CR, Snoeck MMJ, Urwyler A, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth. 2010;105:417–20.PubMedCrossRef
27.
go back to reference Campbell IT, Ellis FR, Evans RT. Metabolic rate and blood hormone and metabolite levels of individuals susceptible to malignant hyperpyrexia at rest and in response to food and mild exercise. Anesthesiology. 1981;55:46–52.PubMedCrossRef Campbell IT, Ellis FR, Evans RT. Metabolic rate and blood hormone and metabolite levels of individuals susceptible to malignant hyperpyrexia at rest and in response to food and mild exercise. Anesthesiology. 1981;55:46–52.PubMedCrossRef
28.
go back to reference Leon LR, Gordon CJ, Helwig BG, Rufolo DM, Blaha MD. Thermoregulatory, behavioral, and metabolic responses to heatstroke in a conscious mouse model. Am J Physiol Regul Integr Comp Physiol. 2010;299:R241–248.PubMedCrossRef Leon LR, Gordon CJ, Helwig BG, Rufolo DM, Blaha MD. Thermoregulatory, behavioral, and metabolic responses to heatstroke in a conscious mouse model. Am J Physiol Regul Integr Comp Physiol. 2010;299:R241–248.PubMedCrossRef
29.
go back to reference King MA, Ward MD, Mayer TA, Plamper ML, Madsen CM, Cheuvront SN, et al. Influence of prior illness on exertional heat stroke presentation and outcome. PLoS ONE. 2019;14:e0221329.PubMedPubMedCentralCrossRef King MA, Ward MD, Mayer TA, Plamper ML, Madsen CM, Cheuvront SN, et al. Influence of prior illness on exertional heat stroke presentation and outcome. PLoS ONE. 2019;14:e0221329.PubMedPubMedCentralCrossRef
30.
go back to reference Roberts WO, Dorman JC, Bergeron MF. Recurrent heat stroke in a runner: race simulation testing for return to activity. Med Sci Sports Exerc. 2016;48:785–9.PubMedCrossRef Roberts WO, Dorman JC, Bergeron MF. Recurrent heat stroke in a runner: race simulation testing for return to activity. Med Sci Sports Exerc. 2016;48:785–9.PubMedCrossRef
31.
32.
go back to reference Knight N, Parkin J, Smith R, Kipps C. The incidence of exertional heat stroke during mass-participation triathlon races: optimising athlete safety. Br J Sports Med. 2017;51:344–5.CrossRef Knight N, Parkin J, Smith R, Kipps C. The incidence of exertional heat stroke during mass-participation triathlon races: optimising athlete safety. Br J Sports Med. 2017;51:344–5.CrossRef
33.
go back to reference Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology. 2009;110:89–94.PubMedCrossRef Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology. 2009;110:89–94.PubMedCrossRef
35.
go back to reference Wappler F. Anesthesia for patients with a history of malignant hyperthermia. Curr Opin Anaesthesiol. 2010;23:417–22.PubMedCrossRef Wappler F. Anesthesia for patients with a history of malignant hyperthermia. Curr Opin Anaesthesiol. 2010;23:417–22.PubMedCrossRef
36.
go back to reference Monnier N, Krivosic-Horber R, Payen J-F, Kozak-Ribbens G, Nivoche Y, Adnet P, et al. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology. 2002;97:1067–74.PubMedCrossRef Monnier N, Krivosic-Horber R, Payen J-F, Kozak-Ribbens G, Nivoche Y, Adnet P, et al. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology. 2002;97:1067–74.PubMedCrossRef
37.
go back to reference Bachand M, Vachon N, Boisvert M, Mayer FM, Chartrand D. Clinical reassessment of malignant hyperthermia in Abitibi-Témiscamingue. Can J Anaesth. 1997;44:696–701.PubMedCrossRef Bachand M, Vachon N, Boisvert M, Mayer FM, Chartrand D. Clinical reassessment of malignant hyperthermia in Abitibi-Témiscamingue. Can J Anaesth. 1997;44:696–701.PubMedCrossRef
38.
go back to reference Brady JE, Sun LS, Rosenberg H, Li G. Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001–2005. Anesth Analg. 2009;109:1162–6.PubMedCrossRef Brady JE, Sun LS, Rosenberg H, Li G. Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001–2005. Anesth Analg. 2009;109:1162–6.PubMedCrossRef
39.
go back to reference Harmer AR, Ruell PA, Hunter SK, McKenna MJ, Thom JM, Chisholm DJ, et al. Effects of type 1 diabetes, sprint training and sex on skeletal muscle sarcoplasmic reticulum Ca2+ uptake and Ca2+-ATPase activity. J Physiol (Lond). 2014;592:523–35.CrossRef Harmer AR, Ruell PA, Hunter SK, McKenna MJ, Thom JM, Chisholm DJ, et al. Effects of type 1 diabetes, sprint training and sex on skeletal muscle sarcoplasmic reticulum Ca2+ uptake and Ca2+-ATPase activity. J Physiol (Lond). 2014;592:523–35.CrossRef
40.
go back to reference Dhaese HL, Martens PR, Müller NH, Casier IM, Mulier JPJ, Heytens L. The use of emergency medical cooling system pads in the treatment of malignant hyperthermia. Eur J Anaesthesiol. 2010;27:83–5.PubMedCrossRef Dhaese HL, Martens PR, Müller NH, Casier IM, Mulier JPJ, Heytens L. The use of emergency medical cooling system pads in the treatment of malignant hyperthermia. Eur J Anaesthesiol. 2010;27:83–5.PubMedCrossRef
41.
go back to reference Harrison GG. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth. 1975;47:62–5.PubMedCrossRef Harrison GG. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth. 1975;47:62–5.PubMedCrossRef
42.
go back to reference Fiszer D, Shaw M-A, Fisher NA, Carr IM, Gupta PK, Watkins EJ, et al. Next-generation sequencing of RYR1 and CACNA1S in malignant hyperthermia and exertional heat illness. Anesthesiology. 2015;122:1033–46.CrossRef Fiszer D, Shaw M-A, Fisher NA, Carr IM, Gupta PK, Watkins EJ, et al. Next-generation sequencing of RYR1 and CACNA1S in malignant hyperthermia and exertional heat illness. Anesthesiology. 2015;122:1033–46.CrossRef
43.
go back to reference Mungunsukh O, Deuster P, Muldoon S, O’Connor F, Sambuughin N. Estimating prevalence of malignant hyperthermia susceptibility through population genomics data. Br J Anaesth. 2019;123:e461–e463463.PubMedCrossRef Mungunsukh O, Deuster P, Muldoon S, O’Connor F, Sambuughin N. Estimating prevalence of malignant hyperthermia susceptibility through population genomics data. Br J Anaesth. 2019;123:e461–e463463.PubMedCrossRef
44.
go back to reference Riazi S, Kraeva N, Hopkins PM. Malignant hyperthermia in the post-genomics era: new perspectives on an old concept. Anesthesiology. 2018;128:168–80.PubMedCrossRef Riazi S, Kraeva N, Hopkins PM. Malignant hyperthermia in the post-genomics era: new perspectives on an old concept. Anesthesiology. 2018;128:168–80.PubMedCrossRef
45.
go back to reference Protasi F, Paolini C, Dainese M. Calsequestrin-1: a new candidate gene for malignant hyperthermia and exertional/environmental heat stroke. J Physiol (Lond). 2009;587:3095–100.CrossRef Protasi F, Paolini C, Dainese M. Calsequestrin-1: a new candidate gene for malignant hyperthermia and exertional/environmental heat stroke. J Physiol (Lond). 2009;587:3095–100.CrossRef
47.
go back to reference Tayeb OS, Marzouki ZM. Effect of dantrolene pretreatment on heat stroke in sheep. Pharmacol Res. 1990;22:565–72.PubMedCrossRef Tayeb OS, Marzouki ZM. Effect of dantrolene pretreatment on heat stroke in sheep. Pharmacol Res. 1990;22:565–72.PubMedCrossRef
48.
go back to reference Channa AB, Seraj MA, Saddique AA, Kadiwal GH, Shaikh MH, Samarkandi AH. Is dantrolene effective in heat stroke patients? Crit Care Med. 1990;18:290–2.PubMedCrossRef Channa AB, Seraj MA, Saddique AA, Kadiwal GH, Shaikh MH, Samarkandi AH. Is dantrolene effective in heat stroke patients? Crit Care Med. 1990;18:290–2.PubMedCrossRef
49.
go back to reference Bouchama A, Cafege A, Devol EB, Labdi O, El-Assil K, Seraj M. Ineffectiveness of dantrolene sodium in the treatment of heatstroke. Crit Care Med. 1991;19:176–80.PubMedCrossRef Bouchama A, Cafege A, Devol EB, Labdi O, El-Assil K, Seraj M. Ineffectiveness of dantrolene sodium in the treatment of heatstroke. Crit Care Med. 1991;19:176–80.PubMedCrossRef
50.
go back to reference Moran D, Epstein Y, Wiener M, Horowitz M. Dantrolene and recovery from heat stroke. Aviat Space Environ Med. 1999;70:987–9.PubMed Moran D, Epstein Y, Wiener M, Horowitz M. Dantrolene and recovery from heat stroke. Aviat Space Environ Med. 1999;70:987–9.PubMed
51.
go back to reference Kalow W, Britt BA, Terreau ME, Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet. 1970;2:895–8.PubMedCrossRef Kalow W, Britt BA, Terreau ME, Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet. 1970;2:895–8.PubMedCrossRef
52.
go back to reference Ellis FR, Harriman DG, Keaney NP, Kyei-Mensah K, Tyrrell JH. Halothane-induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth. 1971;43:721–2.PubMed Ellis FR, Harriman DG, Keaney NP, Kyei-Mensah K, Tyrrell JH. Halothane-induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth. 1971;43:721–2.PubMed
53.
go back to reference Kalow W, Britt BA, Richter A. The caffeine test of isolated human muscle in relation to malignant hyperthermia. Can Anaesth Soc J. 1977;24:678–94.PubMedCrossRef Kalow W, Britt BA, Richter A. The caffeine test of isolated human muscle in relation to malignant hyperthermia. Can Anaesth Soc J. 1977;24:678–94.PubMedCrossRef
54.
go back to reference Bendahan D, Guis S, Monnier N, Kozak-Ribbens G, Lunardi J, Ghattas B, et al. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia. Acta Anaesthesiol Scand. 2004;48:1019–27.PubMedCrossRef Bendahan D, Guis S, Monnier N, Kozak-Ribbens G, Lunardi J, Ghattas B, et al. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia. Acta Anaesthesiol Scand. 2004;48:1019–27.PubMedCrossRef
55.
go back to reference The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth. 1984;56:1267–9.CrossRef The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth. 1984;56:1267–9.CrossRef
56.
go back to reference Zullo A, Textor M, Elischer P, Mall S, Alt A, Klingler W, et al. Voltage modulates halothane-triggered Ca2+ release in malignant hyperthermia-susceptible muscle. J Gen Physiol. 2018;150:111–25.PubMedPubMedCentralCrossRef Zullo A, Textor M, Elischer P, Mall S, Alt A, Klingler W, et al. Voltage modulates halothane-triggered Ca2+ release in malignant hyperthermia-susceptible muscle. J Gen Physiol. 2018;150:111–25.PubMedPubMedCentralCrossRef
57.
go back to reference Klein MG, Simon BJ, Schneider MF. Effects of caffeine on calcium release from the sarcoplasmic reticulum in frog skeletal muscle fibres. J Physiol (Lond). 1990;425:599–626.CrossRef Klein MG, Simon BJ, Schneider MF. Effects of caffeine on calcium release from the sarcoplasmic reticulum in frog skeletal muscle fibres. J Physiol (Lond). 1990;425:599–626.CrossRef
58.
go back to reference Hopkins PM, Rüffert H, Snoeck MM, Girard T, Glahn KPE, Ellis FR, et al. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth. 2015;115:531–9.PubMedCrossRef Hopkins PM, Rüffert H, Snoeck MM, Girard T, Glahn KPE, Ellis FR, et al. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth. 2015;115:531–9.PubMedCrossRef
59.
go back to reference Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand. 1997;41:955–66.PubMedCrossRef Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand. 1997;41:955–66.PubMedCrossRef
60.
go back to reference Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology. 1998;88:579–88.PubMedCrossRef Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology. 1998;88:579–88.PubMedCrossRef
61.
go back to reference Kindler CH, Girard T, Gong D, Urwyler A. The differential effect of halothane and 1,2-dichlorohexafluorocyclobutane on in vitro muscle contractures of patients susceptible to malignant hyperthermia. Anesth Analg. 2002;94:1028–33.PubMedCrossRef Kindler CH, Girard T, Gong D, Urwyler A. The differential effect of halothane and 1,2-dichlorohexafluorocyclobutane on in vitro muscle contractures of patients susceptible to malignant hyperthermia. Anesth Analg. 2002;94:1028–33.PubMedCrossRef
62.
go back to reference Heytens L, Martin JJ, Van de Kelft E, Bossaert LL. In vitro contracture tests in patients with various neuromuscular diseases. Br J Anaesth. 1992;68:72–5.PubMedCrossRef Heytens L, Martin JJ, Van de Kelft E, Bossaert LL. In vitro contracture tests in patients with various neuromuscular diseases. Br J Anaesth. 1992;68:72–5.PubMedCrossRef
63.
go back to reference Oku S, Mukaida K, Nosaka S, Sai Y, Maehara Y, Yuge O. Comparison of the in vitro caffeine-halothane contracture test with the Ca-induced Ca release rate test in patients suspected of having malignant hyperthermia susceptibility. J Anesth. 2000;14:6–13.PubMedCrossRef Oku S, Mukaida K, Nosaka S, Sai Y, Maehara Y, Yuge O. Comparison of the in vitro caffeine-halothane contracture test with the Ca-induced Ca release rate test in patients suspected of having malignant hyperthermia susceptibility. J Anesth. 2000;14:6–13.PubMedCrossRef
64.
go back to reference Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80:771–9.PubMedCrossRef Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80:771–9.PubMedCrossRef
65.
go back to reference Wappler F, Roewer N, Kochling A, Scholz J, Loscher W, Steinfath M, et al. Effects of the Serotonin2Receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients. Anesthesiology. 1996;84:1280–7.CrossRef Wappler F, Roewer N, Kochling A, Scholz J, Loscher W, Steinfath M, et al. Effects of the Serotonin2Receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients. Anesthesiology. 1996;84:1280–7.CrossRef
66.
go back to reference Lee MA, McGlinch EB, McGlinch MC, Capacchione JF. Malignant hyperthermia susceptibility and fitness for duty. Mil Med. 2017;182:e1854–e18571857.PubMedCrossRef Lee MA, McGlinch EB, McGlinch MC, Capacchione JF. Malignant hyperthermia susceptibility and fitness for duty. Mil Med. 2017;182:e1854–e18571857.PubMedCrossRef
68.
go back to reference Zvaritch E, Gillies R, Kraeva N, Richer M, Jungbluth H, Riazi S. Fatal awake malignant hyperthermia episodes in a family with malignant hyperthermia susceptibility: a case series. Can J Anaesth. 2019;66:540–5.PubMedCrossRef Zvaritch E, Gillies R, Kraeva N, Richer M, Jungbluth H, Riazi S. Fatal awake malignant hyperthermia episodes in a family with malignant hyperthermia susceptibility: a case series. Can J Anaesth. 2019;66:540–5.PubMedCrossRef
69.
go back to reference Hunter SL, Rosenberg H, Tuttle GH, DeWalt JL, Smodic R, Martin J. Malignant hyperthermia in a college football player. Phys Sportsmed. 1987;15:77–81.CrossRef Hunter SL, Rosenberg H, Tuttle GH, DeWalt JL, Smodic R, Martin J. Malignant hyperthermia in a college football player. Phys Sportsmed. 1987;15:77–81.CrossRef
70.
go back to reference Pamukcoglu T. Sudden death due to malignant hyperthermia. Am J Forensic Med Pathol. 1988;9:161–2.PubMedCrossRef Pamukcoglu T. Sudden death due to malignant hyperthermia. Am J Forensic Med Pathol. 1988;9:161–2.PubMedCrossRef
71.
go back to reference Kozak-Ribbens G, Bendahan D, Rodet L, Confort-Gouny S, Miri A, Talmant A, et al. Metabolic events with spontaneous malignant hyperthermia crisis in an anaesthetized pig. Can J Anaesth. 1997;44:757–64.PubMedCrossRef Kozak-Ribbens G, Bendahan D, Rodet L, Confort-Gouny S, Miri A, Talmant A, et al. Metabolic events with spontaneous malignant hyperthermia crisis in an anaesthetized pig. Can J Anaesth. 1997;44:757–64.PubMedCrossRef
72.
go back to reference Gatz EE, Wingard DW. Malignant hyperthermia. Nebr Med J. 1973;58:434–7.PubMed Gatz EE, Wingard DW. Malignant hyperthermia. Nebr Med J. 1973;58:434–7.PubMed
73.
go back to reference Groom L, Muldoon SM, Tang ZZ, Brandom BW, Bayarsaikhan M, Bina S, et al. Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families. Anesthesiology. 2011;115:938–45.CrossRef Groom L, Muldoon SM, Tang ZZ, Brandom BW, Bayarsaikhan M, Bina S, et al. Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families. Anesthesiology. 2011;115:938–45.CrossRef
74.
go back to reference Ellis KO, Castellion AW, Honkomp LJ, Wessels FL, Carpenter JE, Halliday RP. Dantrolene, a direct acting skeletal muscle relaxant. J Pharm Sci. 1973;62:948–51.PubMedCrossRef Ellis KO, Castellion AW, Honkomp LJ, Wessels FL, Carpenter JE, Halliday RP. Dantrolene, a direct acting skeletal muscle relaxant. J Pharm Sci. 1973;62:948–51.PubMedCrossRef
75.
go back to reference Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene–a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004;59:364–73.PubMedCrossRef Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene–a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004;59:364–73.PubMedCrossRef
Metadata
Title
Overlapping Mechanisms of Exertional Heat Stroke and Malignant Hyperthermia: Evidence vs. Conjecture
Authors
Orlando Laitano
Kevin O. Murray
Lisa R. Leon
Publication date
01-09-2020
Publisher
Springer International Publishing
Published in
Sports Medicine / Issue 9/2020
Print ISSN: 0112-1642
Electronic ISSN: 1179-2035
DOI
https://doi.org/10.1007/s40279-020-01318-4

Other articles of this Issue 9/2020

Sports Medicine 9/2020 Go to the issue